MetaCap

Journey Medical (DERM) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Unicycive Therapeutics (UNCY) has outperformed Journey Medical (DERM) over the past year, losing 38.0% versus a loss of 55.8%. Over five years, DERM leads with a -61.1% price change compared with -88.5% for UNCY. Unicycive Therapeutics is the larger company by market cap ($97.8 million vs $93.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DERM-55.76%UNCY-37.96%
+64%+1%-61%
Nov 21, 20251 yearNov 20, 2026
DERM-62.46%UNCY-87.07%
+18%-38%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DERM versus UNCY key metrics
MetricDERMUNCY
Share price$3.30$3.35
Market cap$93.16M$97.77M
1-day change-7.04%-5.10%
YTD return-57.20%-41.94%
1-year return-55.76%-37.96%
5-year return-61.13%-88.53%
Forward P/E—4.86
EPS (TTM)$-0.18$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$61.86M—
Revenue growth (YoY)+10.20%—
Net income (latest FY)$-11.43M$-26.55M
Gross margin66.17%—
Operating margin-13.21%—
Net margin-18.48%—
52-week high$9.56$8.74
52-week low$3.21$3.33
Distance from 52-week high-65.46%-61.67%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+286.36%+685.07%
Average volume190.39K963.80K
Shares outstanding22.23M29.18M
Employees5821
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UNCY has outperformed DERM by 17.8 percentage points over the past year.

About Journey Medical

DERM stock →

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

DERM vs UNCY FAQ

Which is bigger, Journey Medical or Unicycive Therapeutics?

Unicycive Therapeutics (UNCY) is larger, with a market capitalization of $97.77M compared with $93.16M for Journey Medical (DERM).

Which stock has performed better over the past year, DERM or UNCY?

UNCY returned -37.96% over the past 12 months, compared with -55.76% for DERM (price return, excluding dividends). Past performance does not predict future results.

Are Journey Medical and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons